VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector. VALBIOTIS has been listed on Euronext Growth since 7 June 2017.
Analyst: Christophe Dombu / Mohamed Kaabouni
Analyst: Thibaut Voglimacci-Stephanopoli